We are live on ! Find out more
BC

Boxer Capital Portfolio holdings

AUM $2.04B
1-Year Est. Return 108.39%
This Fund
S&P 500
This Quarter Est. Return
+0.31%
1 Year Est. Return
+108.39%
3 Year Est. Return
+261.8%
5 Year Est. Return
+1,135.09%
10 Year Est. Return
–
AUM
$2.95B
AUM Growth
-$162M
Cap. Flow
+$94.6M
Cap. Flow %
3.21%
Top 10 Hldgs %
48.26%
Holding
91
New
14
Increased
7
Reduced
3
Closed
6

Top Buys

Rank Stock Value
1
MRTX
Mirati Therapeutics, Inc. Common Stock
MRTX
+$46.4M
2
CGEM icon
Cullinan Oncology
CGEM
+$43.6M
3
NUVB icon
Nuvation Bio
NUVB
+$39.6M
4
CNTB
Connect Biopharma Holdings
CNTB
+$35.4M
5
IMVT icon
Immunovant
IMVT
+$26.4M

Top Sells

Rank Stock Value
1
ONC
BeOne Medicines Ltd
ONC
+$116M
2
PAND
Pandion Therapeutics Inc. Common Stock
PAND
+$31.3M
3
PRVL
Prevail Therapeutics Inc. Common Stock
PRVL
+$25.9M
4
LABD icon
Direxion Daily S&P Biotech Bear 3X ETF
LABD
+$19.4M
5
CLDX icon
Celldex Therapeutics
CLDX
+$17.5M

Sector Composition

Rank Sector Weight
1 Healthcare 96.52%
2 Financials 0.94%
Name Market Value Portfolio Weight Shares or Principal Change
in Stake 		Capital Flow
BCAB icon
26
BioAtla
BCAB
$5.46M
$34.9M 1.18%
13,727
– –
ALGS icon
27
Aligos Therapeutics
ALGS
$26.2M
$34.7M 1.18%
61,042
– –
BCEL
28
DELISTED
Atreca, Inc. Class A Common Stock
BCEL
$33.8M 1.15%
2,202,333
– –
PASG icon
29
Passage Bio
PASG
$14.4M
$33.7M 1.14%
96,416
– –
KNTE
30
DELISTED
Kinnate Biopharma Inc. Common Stock
KNTE
$33.2M 1.13%
1,065,939
+1,274
+0.1% +$44.4K
KURA icon
31
Kura Oncology
KURA
$800M
$29.7M 1.01%
1,050,289
– –
ANAB icon
32
AnaptysBio
ANAB
$1.58B
$28M 0.95%
1,300,000
– –
LABD icon
33
Direxion Daily S&P Biotech Bear 3X ETF
LABD
$71M
$27.2M 0.92%
125,000
-100,000
-44% -$19.4M
ACHL
34
DELISTED
Achilles Therapeutics
ACHL
$25.4M 0.86%
+1,536,208
New +$25.4M
RNAM
35
DELISTED
Avidity Biosciences
RNAM
$24.5M 0.83%
1,121,327
– –
KDMN
36
DELISTED
Kadmon Holdings, Inc.
KDMN
$24.1M 0.82%
6,205,882
– –
AKRO
37
DELISTED
Akero Therapeutics
AKRO
$24.1M 0.82%
831,495
– –
GOSS icon
38
Gossamer Bio
GOSS
$82.9M
$23.7M 0.8%
2,562,358
– –
SLDB icon
39
Solid Biosciences
SLDB
$794M
$23.4M 0.79%
282,305
– –
FOLD
40
DELISTED
Amicus Therapeutics
FOLD
$23M 0.78%
2,325,000
– –
MREO
41
Mereo BioPharma
MREO
$54.7M
$21M 0.71%
6,226,673
– –
EPIX
42
DELISTED
ESSA Pharma
EPIX
$20M 0.68%
+687,000
New +$16M
TLIS
43
DELISTED
Talis Biomedical Corporation Common Stock
TLIS
$19.9M 0.68%
+103,400
New +$25.8M
ODT
44
DELISTED
Odonate Therapeutics, Inc. Common Stock
ODT
$19.2M 0.65%
5,607,086
– –
BMRN icon
45
BioMarin Pharmaceuticals
BMRN
$11.6B
$18.9M 0.64%
250,000
– –
NGNE icon
46
Neurogene
NGNE
$656M
$18.5M 0.63%
75,053
– –
CBAY
47
DELISTED
Cymabay Therapeutics
CBAY
$18.2M 0.62%
4,000,000
– –
CABA icon
48
Cabaletta Bio
CABA
$437M
$17.8M 0.6%
1,603,361
– –
IRON icon
49
Disc Medicine
IRON
$2.96B
$17.6M 0.6%
+43,333
New +$19.3M
IMVT icon
50
Immunovant
IMVT
$7.93B
$16M 0.54%
+1,000,000
New +$26.4M
1
2
3 4

Similar funds

FTDI
First Trust Direct Indexing Boston, Massachusetts $1.87B AUM 43.63% 1-Year Est. Return
CIM
Contrarius Investment Management St. Helier, Jersey $1.76B AUM 35.87% 1-Year Est. Return
PRO
Pensioenfonds Rail & OV Utrecht, Netherlands $1.44B AUM 23.73% 1-Year Est. Return
GFS
GYL Financial Synergies West Hartford, Connecticut $1.33B AUM 34.46% 1-Year Est. Return
ECM
Ensemble Capital Management San Francisco, California $1.18B AUM 41.81% 1-Year Est. Return
CIP
Chartwell Investment Partners Berywn, Pennsylvania $2.91B AUM 40.48% 1-Year Est. Return
SEC
Seven Eight Capital New York $1.11B AUM 29.48% 1-Year Est. Return
CAC
Cowen and Company New York $2.97B AUM 105.26% 1-Year Est. Return

Boxer Capital's Q1 2021 Portfolio in Review

As of Q1 2021, Boxer Capital held 91 positions worth $2.95B, down 5.2% from $3.11B the previous quarter. Its ten largest holdings account for 48% of the portfolio.

Boxer Capital deployed $94.6M of net new capital in Q1 2021, opening 14 new positions and adding to 7 existing holdings. Its largest new stake was Cullinan Oncology: 1,074,082 shares worth $44.8M.

By sector, the portfolio is most concentrated in Healthcare at 97% of assets, down from 97% a quarter earlier, followed by Financials.

On the sell side, the largest reduction was BeOne Medicines Ltd, an estimated $116M trimmed.

  • Boxer Capital's largest Q1 2021 buy was Cullinan Oncology: 1,074,082 shares worth $44.8M.
  • Boxer Capital added most to Mirati Therapeutics, Inc. Common Stock in Q1 2021, an estimated $46.4M increase.
  • Boxer Capital's biggest Q1 2021 reduction was BeOne Medicines Ltd, cutting an estimated $116M.
  • Boxer Capital fully exited Pandion Therapeutics Inc. Common Stock in Q1 2021, selling an estimated $31.3M.
  • Boxer Capital's ten largest holdings make up 48% of its $2.95B portfolio in Q1 2021.
  • Boxer Capital opened 14 new positions and closed 6 in Q1 2021.
  • Boxer Capital's portfolio value fell 5.2% quarter-over-quarter to $2.95B.

Based on Boxer Capital's 13F filing for Q1 2021, filed 17 May 2021.